Metropolitan Life Insurance Company (MetLife)’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-3,537
| Closed | -$609K | – | 2880 |
|
|
2021
Q3 | $609K | Sell |
3,537
-116
| -3% | -$15.2K | 0.01% | 1320 |
|
|
2021
Q2 | $458K | Buy |
3,653
+80
| +2% | +$10.1K | 0.01% | 1573 |
|
|
2021
Q1 | $485K | Sell |
3,573
-156
| -4% | -$20.2K | 0.01% | 1435 |
|
|
2020
Q4 | $477K | Sell |
3,729
-73
| -2% | -$8.56K | 0.01% | 1381 |
|
|
2020
Q3 | $428K | Buy |
3,802
+317
| +9% | +$31.6K | 0.01% | 1315 |
|
|
2020
Q2 | $332K | Sell |
3,485
-9,953
| -74% | -$959K | 0.01% | 1486 |
|
|
2020
Q1 | $1.21M | Sell |
13,438
-528
| -4% | -$41K | 0.02% | 599 |
|
|
2019
Q4 | $740K | Sell |
13,966
-324
| -2% | -$14.8K | 0.01% | 1091 |
|
|
2019
Q3 | $565K | Buy |
14,290
+327
| +2% | +$14.2K | 0.01% | 1208 |
|
|
2019
Q2 | $574K | Hold |
13,963
| – | – | 0.01% | 1225 |
|
|
2019
Q1 | $650K | Buy |
13,963
+1,563
| +13% | +$68.6K | 0.01% | 1129 |
|
|
2018
Q4 | $540K | Buy |
12,400
+166
| +1% | +$8.29K | 0.01% | 1150 |
|
|
2018
Q3 | $700K | Hold |
12,234
| – | – | 0.01% | 1137 |
|
|
2018
Q2 | $594K | Hold |
12,234
| – | – | 0.01% | 1196 |
|
|
2018
Q1 | $478K | Buy |
12,234
+266
| +2% | +$11.3K | 0.01% | 1307 |
|
|
2017
Q4 | $508K | Sell |
11,968
-32,196
| -73% | -$1.21M | 0.01% | 1279 |
|
|
2017
Q3 | $1.65M | Buy |
44,164
+22,082
| +100% | +$767K | 0.01% | 1009 |
|
|
2017
Q2 | $671K | Buy |
22,082
+1,865
| +9% | +$54K | ﹤0.01% | 1483 |
|
|
2017
Q1 | $535K | Hold |
20,217
| – | – | ﹤0.01% | 1604 |
|
|
2016
Q4 | $516K | Hold |
20,217
| – | – | ﹤0.01% | 1705 |
|
|
2016
Q3 | $732K | Hold |
20,217
| – | – | 0.01% | 1464 |
|
|
2016
Q2 | $687K | Buy |
20,217
+1,850
| +10% | +$60.1K | 0.01% | 1496 |
|
|
2016
Q1 | $485K | Buy |
18,367
+2,821
| +18% | +$82K | ﹤0.01% | 1589 |
|
|
2015
Q4 | $758K | Hold |
15,546
| – | – | 0.01% | 1343 |
|
|
2015
Q3 | $387K | Sell |
15,546
-298
| -2% | -$8.96K | ﹤0.01% | 1804 |
|
|
2015
Q2 | $501K | Buy |
15,844
+2,859
| +22% | +$92.3K | ﹤0.01% | 1743 |
|
|
2015
Q1 | $494K | Hold |
12,985
| – | – | ﹤0.01% | 1567 |
|
|
2014
Q4 | $506K | Hold |
12,985
| – | – | ﹤0.01% | 1757 |
|
|
2014
Q3 | $393K | Hold |
12,985
| – | – | ﹤0.01% | 1873 |
|
|
2014
Q2 | $441K | Buy |
12,985
+7,603
| +141% | +$254K | ﹤0.01% | 1926 |
|
|
2014
Q1 | $186K | Sell |
5,382
-3,057
| -36% | -$138K | ﹤0.01% | 2512 |
|
|
2013
Q4 | $334K | Buy |
+8,439
| New | +$204K | ﹤0.01% | 2104 |
|
Metropolitan Life Insurance Company (MetLife)'s XLRN Position: Q4 2021 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 3,537 shares — an estimated $609K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $1.65M in Q3 2017. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 3,537 Acceleron Pharma shares in Q4 2021, an estimated $609K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Acceleron Pharma position peaked at $1.65M in Q3 2017.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.